Five-year immunity persistence following immunization with haemophilus influenzae type b conjugate vaccine.
10.3760/cma.j.cn112338-20220526-00467
- VernacularTitle:b型流感嗜血杆菌结合疫苗接种后5年的免疫持久性观察
- Author:
Ming Wei WEI
1
;
Jing Xin LI
1
;
Kai CHU
1
;
Jia Hong ZHU
2
;
Feng Cai ZHU
1
Author Information
1. Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
2. Program Office, Lianshui County Center for Disease Control and Prevention, Huai'an 223499, China.
- Publication Type:Journal Article
- MeSH:
Child;
Infant;
Humans;
Vaccines, Conjugate;
Haemophilus influenzae type b;
Immunization;
Vaccination;
Antibodies, Bacterial
- From:
Chinese Journal of Epidemiology
2022;43(11):1768-1772
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the immunity persistence five years later after immunization with Haemophilus influenzae type b (Hib) conjugate vaccine in healthy infants/children aged 3 months to 5 years in China. Methods: The children were subjects who completed the whole-schedule immunization in the phase Ⅲ clinical trial in Lianshui county of Jiangsu povince was selected for the collection of blood samples at 5 years after vaccination from November to December, 2019. The enzyme-linked immunosorbent assay (ELISA) was used to detect Hib polyribosyl-ribitol-phosphate antibody (anti-Hib-PRP), and the long-term/short-term protection rate, geometric mean concentration (GMC) and geometric mean concentration increase fold (GMFI) of serum anti-Hib-PRP were calculated. Results: A total of 580 children were enrolled in this study, of which 158, 207 and 215 belonged to 3-5 month age group, 6-11 month age group and 1-5 year age group, respectively. The short-term (≥0.15 μg/ml)/long-term (≥1.0 μg/ml) protection rates of serum anti-PRP in the three groups after immunization were 89.24%, 90.34% and 98.60%, respectively; the GMC were 3.95 μg/ml, 3.11 μg/ml and 10.01 μg/ml respectively, and the GMFI were 29.04, 11.01 and 3.26 respectively. Conclusions: Hib conjugate vaccine can still have good immunogenicity after 5 years of primary immunization in healthy infants/children aged 3 months to 5 years in China.
